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Cardiac arrhythmias are the principal cause of sudden death due to heart disease, and current 
therapy is inadequate. A novel approach for formulating a lidocaine-polyurethane controlled 
release matrix and implanting this drug delivery system directly onto the arrhythmic epicardium 
is reported. Lidocaine-HCl-polyurethane matrices (28% w/w) were fabricated and studied for 
their in vitro drug release into physiologic buffer, and their in vivo pharmacologic effectiveness 
in rapidly converting ouabain-induced ventricular tachycardia in dogs to normal sinus rhythm. 
In vitro lidocaine release was successfully modulated as a result of variations in fabrication: 
compression molding, and stirring duringpolymer synthesis. Lidocaine release in vitro from the 
most rapidly releasing matrix formulation delivered more than 40% of the contained drug deliv- 
ered after only 20 minutes, and the remainder slowly released over one week or more. Direct 
epimyocardial placement of this formulation resulted in the prompt conversion of ouabain-in- 
duced ventricular tachycardia to normal sinus rhythm in all experimental animals (n ~6) studied 
in 1.5 t 0.77 min. (mean Ifr standard error), while controls (n = 4) had persistent ventricular tach- 
ycardia for more than 60 min. Site-specific therapy was as rapid as intravenous administration, 
but with lower plasma lidocaine levels after comparable dosages. It is concluded that lidocaine- 
polyurethane controlled release matrices can be fabricated with a broad range of initial release 
profiles, and that these matrices can rapidly initiate the conversion of ouabain-induced ventric- 
ular tachycardia to normal sinus rhythm. 
INTRODUCTION 
Ventricular arrhythmias are the principal 
cause of sudden death in acute myocardial in- 
farction, and frequently complicate the medical 
and surgical treatment of a wide array of car- 
diac diseases [ 11. However, conventional ther- 
apy is often ineffective in either preventing or 
*Address for correspondence: Robert J. Levy, M.D., Kresge Implantable controlled release drug delivery 
II, Room 5080, Box 0576, The University of Michigan, Ann systems have received increasing attention over 
Arbor, Michigan 48109-0576, U.S.A. Phone: 313-9362850. the past decade [4-71, and represent an impor- 
rapidly treating life-threatening ventricular ar- 
rhythmias, due to inadequate myocardial drug 
concentrations and adverse effects [ 21. Lido- 
Caine is a widely used antiarrhythmic agent for 
the therapy of ventricular tachycardia [ 31. 
Nevertheless, this compound is only effective 
clinically when given intravenously, and its use 
is frequently associated with untoward drug ef- 
fects [3]. 
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tant and emerging area of research, which may 
be useful in the therapy of a wide variety of dis- 
ease processes, including cardiac arrhythmias. 
The primary goal of this type of site-specific 
drug administration is the prolonged delivery 
of a medication into a particular body compart- 
ment at effective, but minimal local therapeutic 
concentrations, while reducing the risk of gen- 
eralized toxic effects. However, it should be 
noted that ventricular tachycardia is life- 
threatening and its rapid conversion within 
minutes to sinus rhythm is a prerequisite for 
any dosage form. 
The present study examined lidocaine-po- 
lyurethane controlled release matrix formula- 
tions in vitro and tested the novel hypothesis 
that lidocaine could be effectively administered 
transmyocardially by a polymeric matrix, placed 
on the epicardial surface in dogs, for the rapid 
conversion of ouabain-induced ventricular to 
normal sinus rhythm. The objectives of these 
studies were to investigate methodology for 
modulating matrix release of lidocaine, and then 
to study the efficacy and mechanisms of onset 
of action of these formulations in a canine model 
of ouabain-induced ventricular tachycardia. 
MATERIALS AND METHODS 
Lidocaine-HCl (Abbott Inc., Chicago, Ill. ) 
was sieved to a particle size of 75-150 pm 
(U.S.A. standard sieve nos. 100-200, ASTM 
designation Ell, Newark Wire Cloth Co., New- 
ark, N.J.). Matrices were fabricated using the 
Tecoflex 2-80A polyurethane two component 
system (Thermedics, Inc., Woburn, Mass. ) 
combined with lidocaine-HCl (28%w/w lido- 
Caine-polyurethane) and catalyzed by the ad- 
dition of FeCl,,, 0.74 pmol/g polyether (as 5 mg/ 
ml solution in acetone). Typically, 4 parts of 
lidocaine were combined with 10 parts of Te- 
coflex 2-80A using 0.21 parts of the diisocyan- 
ate monomer and 0.79 parts of the polyether 
monomer. Polymeric matrices were formed by 
film casting (2 mm thickness) of the reaction 
mixture, and polymerization for 48 hours at 
55’ C with or without a 2 minute period of stir- 
ring (50 rpm) after two hours of polymeriza- 
tion. Another series of matrices was polymerized 
with compression molding (0.01 ton) of the li- 
docaine-monomers mixture at 55°C with the 
bonding of reinforced Silastic sheeting (501-l 
Dow Corning Corp., Midland, Mich. ) onto one 
of the planar surfaces in order to seal it from 
drug release. Matrices (1 cm x 1 cm samples) 
were released into 10 ml of buffer (pH 7.4,0.05 
M potassium phosphate, 37” C) in polyethyl- 
ene vials on an orbit shaker (100 rpm ). The sol- 
ubilized lidocaine was monitored by absorbance 
at 260 nm, and the data were expressed as the 
means of duplicate measurements. 
Lidocaine measurements utilized a Waters 
high performance liquid chromatograph (Model 
6000A, Waters Inc., Bedford, Mass.) with a 
prepacked Cl8 column (particle size 5 pm), Al- 
tex Ultrasphere-ODS 25 cmx4.6 mm I.D. 
(Beckman Inc., San Ramon, Calif. ), and an is- 
ocratic mobile phase of 0.1 M sodium phos- 
phate buffer pH 3.0 with 0.7% v/v 
triethylamine-acetonitrile (50:50 ). Chromat- 
ographic absorbance was monitored at 210 nm 
[ 9,101. Net in vivo polymeric lidocaine delivery 
was determined by Soxhlet methanolic extrac- 
tion of the residual drug remaining in the po- 
lymeric matrices after use, followed by 
subsequent high performance liquid chromat- 
ographic (HPLC ) analyses [ 9,101. 
Scanning electron micrographs were taken on 
cross-sections of the lidocaine-polyurethane 
matrices. Specimens were sputtered with gold- 
palladium to suppress electron beam-induced 
charging, and were examined with an ISI-DS130 
scanning electron microscope (ISI Inc., Mou- 
tain View, Calif. ). 
Ventricular tachycardia was induced with 
ouabain administration [S] in 12 male mongrel 
dogs (12-14 kg), which had undergone a left 
thoracotomy and pericardotomy under pento- 
barbital anesthesia. Bipolar platinum tip elec- 
trodes (Ethicon, Somerville, N.J.) were sewn 
to the left atria1 appendage, right ventricle, and 
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left ventricular free wall for electrocardi- 
ographic recording. Ouabain (Sigma Inc., St. 
Louis, MO. f was administered at an initial dose 
of 40 pg/kg intravenously at a rate of 40 /lg/ 
min, and at subsequently halved dosages until 
sustained ventricular tachycardia was docu- 
mented on the electrocardiogram (AR6, Ho- 
neywell, Inc., Wellesley, Mass.). The electro- 
cardiogram leadconfi~ration utilizedstandard 
surface limb leads, II and AVR as well as atria1 
and ventricular leads (see Fig. 3 ) . Ten dogs were 
used in the epicardial polymer studies and two 
were given intravenous lidocaine. In each epi- 
cardial adminstration animal, the polymeric 
matrix, either control (non-drug containing) or 
containing lidocaine, was left in place on the 
left ventricular myocardium for the time needed 
to int‘ially convert the ventricular tachycardia 
to normal sinus rhythm, or for one hour. When 
sinus rhythm reappeared, the matrix was re- 
moved after one additional minute, and the ex- 
periment was continued in order to detect the 
return of the arrhythmia. Periodic blood sam- 
pling was carried out to monitor the resulting 
plasma lidocaine levels. Two animals were given 
intravenous lidocaine over 1.5 minutes at dos- 
ages equivalent to the extremes (25 and 45 mg/ 
kg) delivered by the lidocaine-pol~rethane 
patches as determined by Soxhlet analysis (as 
described, above) and these animals were stud- 
ied for comparisons with respect to their lido- 
Caine plasma levels. 
RESULTS 
Controlled release of lidocaine from polyu- 
rethane matrices was achieved with an array of 
formulations possessing a broad range of ki- 
netic profiles. In addition, lidocaine polyure- 
thane matrices successfully and rapidly 
converted ouabain-induced ventricular tachy- 
cardia in dogs to sinus rhythm. 
Control release of lidocaine: In vitro results 
Sustained cumulative release of lidocaine 
from the polyurethane matrices was compara- 
ble between all formulations, however the early 
phase of release could be modulated depending 
upon the synthetic technique used (Fig. 1). 
Matrices formulated with compression mold- 
ing and sealing demonstrated with lowest bulk 
release rates in the first sixty minutes of in uitro 
incubation, compared with polymers fabricated 
by simple film casting techniques and polymer- 
ized over 48 hours. These latter matrices re- 
leased nearly 40% of their contained lidocaine 
after only 20 minutes. Polymers synthesized 
with a disruptive stirring step demonstrated an 
early release phase, which was intermediate in 
rate compared with the previous two 
approaches. 
The differences in release kinetics may be ex- 
plained in part by the surface sealing effects of 
the bonded silastic sheeting, and by the dimin- 
ished ultrastructural porosity noted in the 
stirred matrices compared with that seen in the 
films polymerized by casting at 55°C. These 
important differences in matrix porosity are 
evident in he scanning electron microscopic 
studies of the polymers carried out prior to their 
release (Fig. 2). However, it is of interest that 
post-release scanning electron micrographs re- 
vealed qualitatively greater depletion of the 
granular lidocaine from the non-stirred matri- 
ces compared with either the stirred or 
compression molded-sealed matrices. The seal- 
ing of 50% of the matrix surface in the compres- 
sion molded group probably explains its 
relatively lower release rate. 
Rapid conversion of ventricular tachycardia 
to sinus rhythm in dogs with lidocaine-po- 
lyurethane matrices 
Ouabain-induced ventricular tachycardia in 
dogs was successfully and quickly resolved (Ta- 
ble 1 and Fig. 3) using the most rapidly releas- 
ing matrix formulation (non-stirred, see 
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Fig. 1. Cumulative in vitro drug delivery (monitored by ab- 
sorbance at 260 nm) of lidocaine-HCl (28% w/w loading) 
from polyurethane matrices into pH 7.4 buffer (0.05 M po- 
tassium phosphate), showing short term (A) and sus- 
tained release (B) characteristics. Lidocaine release was 
affected by the following variations in fabrication: q =po- 
lymerization at 55’ C without stirring, n = at 55 3 C with 
brief stirring after 2 hours of polymerization, and 
A =compression molding at 55°C with silastic sealing at 
one side. 
Methods) applied to the left ventricular epicar- 
dium. Ventricular tachycardia was converted to 
sinus rhythm in all treated dogs after 1.5? 0.77 
min. In contrast, control polymer (drug-free 
polyurethane) applications had no effect on the 
course of the ventricular tachycardia, which 
persisted for more than one hour in all experi- 
mental animals. After conversion of ventricu- 
lar tachycardia to sinus rhythm, matrices were 
removed after one minute, and plasma lido- 
Caine levels were noted to typically exhibit a de- 
layed peak (after 1 to 5 minutes ), which was 
four fold or more reduced in magnitude com- 
pared with intravenous administration. The net 
lidocaine dose delivered by the matrices over the 
brief duration of application was quite high, 
ranging from 24.1 to 48.9 mg/kg. Despite this, 
plasma levels of 8.75 to 25.5 pg/ml were noted, 
compared with 36.7-101.2 pg/ml, respectively, 
when the same doses were administered intra- 
venously (Fig. 4 ) . Thus, transmyocardial drug 
delivery appears to result, in extravascular com- 
partmentalization of lidocaine, and relatively 
lower plasma levels compared with intravenous 
administration. 
Three of the six lidocaine controlled release 
animals, which demonstrated conversion of 
ventricular tachycardia to sinus rhythm, expe- 
rienced a resumption of the arrhythmia after 15 
to 25 minutes. These animals had plasma lido- 
Caine levels of 0.64-7.94 pg/ml at the time of 
the resumption of ventricular tachycardia com- 
pared with plasma levels of 1.2-2.9 pg/ml in the 
three animals with persistent sinus rhythm after 
45-60 minutes. Thus, plasma lidocaine proved 
to be an insensitive index of the duration of the 
effectiveness of an initially effective dose of 
transmyocardial lidocaine. 
DISCUSSION 
The present study has investigated the for- 
mulation and modulation of lidocaine-polyu- 
rethane controlled release matrices, as well as 
the effectiveness of short term in uivo release of 
lidocaine for the rapid site-specific conversion 
of ventricular tachycardia to sinus rhythm. Ep- 
icardially placed lidocaine matrices were rap- 
idly effective for site-specific therapy of 
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Fig. 2. Scanning electron micrographs (bar = 500 pm) of lidocaine-polyurethane (28% w/w) matrices before and after five 
minutes release into a physiologic buffer. Lidocaine release from non-stirred matrices is shown before (A) and after release 
(B), illustrating extensive depletion of granular lidocaine via rapid permeation through the open porous structure. Release 
of lidocaine from matrices stirred during polymerization is shown pre- (C) and post-release (D), revealing an extensive 
granular depletion from the matrix structure, although from a less intrinsically porous matrix than noted in (A) and (B). 
Lidocaine release from compression-molded matrices, sealed with Silastic sheeting (arrow), demonstrated the least deple- 
tion in granular lidocaine comparing matrices before (E) and after release (F), due to the compact matrix structure and 
bonded Silastic sealing of one of the potential releasing surfaces. 
TABLE 1 
Ventricular tachycardia (ouabain-induced) response to lidocaine-polyurethane matrices applied to the left. ventricular epi 
cardium in dogs 








No. of animals Time of Duration of 
converted to conversion to drug 
SR SR (min) application 
(min) 
l/l 0.5 1.5 
l/l 0.5 1.5 




















- 6 1 
39.2 L 8.8 16.5t8.c 
,‘Mean -f-standard error, p < 0.001 compared with control with Student’s t-test. 
“Return of ventricular tachycardia (VT) was noted in 3 animals, with the remainder continuing in normal sinus rhythm 
(SR) for > 60 minutes. 
Fig. 3. Ouabain-induced ventricular tachycardia in canines (via a left thoracotomy): experimental polymeric patches 
(3 x 3 x 0.2 cm ), either a control (non-drug containing) or a lidocaine-polyurethane matrix, were separately applied to the 
epicardial left vent.ricular myocardium l-2 cm to the left of the anterior descending coronary artery 1-2 cm below the 
circumflex coronary. Atria1 and ventricular deflect,ions are indicated as “a” and “v”, respect.ivefy, with 0.04~second t.ime 
markings. Conversion of ventricular tachycardia after placement of a lidocaine-polyurethane matrix to normal sinus rhythm 
is clearly observed. 
(~uabain-induced ventricular tachycardia in incompatibiIity, incomplete polymerization, 
dogs. and the insolubility of many hyidrophilic com- 
Polyuret,hane controlled release matrices pounds in the organic solvents used to process 
containing hydrophillic compounds have been polyurethane. These problems have been suc- 
the subject of relatively little previous research. cessfully addressed in the present, st.udy. Lido- 
The reasons for this include dispersant-matrix Caine-HCI proved to be completely compatible 
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Fig. 4. Lidocaine plasma levels (ranges) determined by high 
performance liquid chromatography (HPLC) in canine 
studies of ouabain-induced ventricular tachycardia reflect- 
ing the means of duplicate measurements: (A) The range 
of plasma levels (N= 2) following intravenous administra- 
tion of 25 and 45 mg/kg lidocaine, which were doses cor- 
responding to the epicardial administration achieved in (B ) , 
which illustrates the range of plasma levels (N= 6) and their 
time-dependent decay after epicardial lidocaine-polyure- 
thane therapy (see Table 1). 
and well dispersed in the bulk reagents and was 
stable under the polymerization reaction con- 
ditions used. In addition, the polymerization 
proceeded faster with the addition of a FeCl, 
catalyst. 
Minor modifications in the polymerization 
163 
procedures proved to have potent effects on the 
observed release kinetics in the early phases of 
controlled release. Polymers formed at 55 ’ C for 
48 hours demonstrated the most rapid releasing 
characteristics during the initial phase of the 
incubations. However, stirring of the polymers 
during their formulation, which enhanced re- 
active crosslinking, resulted in a relative dimin- 
ishing of the early phase of release, and this 
effect was probably due to the partial elimina- 
tion of cavities created during the polymeriza- 
tion. Furthermore, compression molding with 
sealing resulted in an even greater limiting of 
the early phase of release, and this was proba- 
bly due to further reduction of these cavities, 
and limiting the releasing surface by bonding of 
impermeable Silastic sheeting. 
The in uiuo suppression of ouabain-induced 
ventricular tachycardia was studied using only 
the matrices with the most rapid releasing 
characteristics in order to demonstrate the ef- 
fectiveness of this route of administration and 
the efficacy of the dosage form per se. A rapid 
onset of effect is a prerequisite of a controlled 
release system for the treatment of ventricular 
tachycardia, since this arrhythmia is often le- 
thal and can, unless promptly treated, progress 
on to an even more dangerous arrhythmia, ven- 
tricular fibrillation. Of additional interest in the 
present results is the apparent late peaking of 
plasma lidocaine levels following transmyocar- 
dial drug delivery, despite the rapid and brief 
period of exposure to the controlled release ma- 
trix. This suggests that a secondary phase of 
controlled release is taking place from the myo- 
cardium, which was exposed to the rapid-re- 
lease polyurethane matrix. 
The plasma lidocaine levels achieved in these 
experimental studies were well below those 
noted after intravenous administration of the 
same net lidocaine dose, but were nevertheless 
higher than those usually considered to be ther- 
apeutic in humans. It is likely that further stud- 
ies of localized experimental arrhythmic foci, 
using perhaps programmed stimulation tech- 
niques rather than systemic ouabain toxicity, 
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will reveal that the dose needed via lidocaine 
matrix administration will be but a fraction of 
that used in the present study. Furthermore, the 
pat.terning of controlled release may in fact 
consist of two separate phases, one concerned 
with the short-term delivery of high levels of 
drug, similar to t.he approach of this work, in 
order to rapidly convert a life-threatening ar- 
rhythmia, and a chronically suppressive phase, 
using lower levels of antiarrhythmic agents to 
prevent the re-emergence of the arrhyt~lmia. 
Polymeric drug delivery of chronotropic 
agents was successfully carried out by others 
using myocardial implants of silicone rubber 
reservoirs containing a variety of compounds 
including digoxin, isoproterenol, and thyroid 
hormone, all of which could effectively accel- 
erate cardiac rate when delivered direct.ly into 
the myocardium [ 111. Epicardial lidocaine has 
been used prior to these studies in experiments 
investigating decreased cardiac output due to 
an epicardial lidocaine drip [ 12 1. This route of 
administration has also been used to effectively 
sympathetectomize the heart, aft,er filling the 
pericardial sac with a lidocaine solution [ 13 1. 
Roth of these previous approaches raise impor- 
tant questions about the mechanism of action 
of epicardial lidocaine and its adverse effects 
when administered by a controlled release 
matrix. 
The eventual clinical ut,ility of this experi- 
mental approach may require that the site of 
matrix placement and the duration of antiar- 
rhyt.hmia drug delivery be varied optimally to 
meet. the needs of the disease process of inter- 
est. A number of potential clinical settings are 
possible, and these would include such appli- 
cations as using a biodegradable epicardial 
polymer for suppression of post-operative ar- 
rhythmias during the first week following open 
heart surgery. Another application might be a 
drug delivery implant to be used instead of or 
as an adjunct to ablative arrhythmia surgery. 
Drug delivery implants could also be put in place 
via cardiac catheterization using screw-tip in- 
sertion t,ech~iques analogous to those used to 
install pacemaker leads. This approach might 
prove to be beneficial to the hundreds of thou- 
sands of patients receiving ineffective conven- 
tional arrhythmia therapy. 
Sustained site-specific cardiac drug delivery 
for periods ranging from weeks to years has been 
demonstrated experimentsally for antibiotic 
therapy to prevent bacterial endocarditis [ 51, 
and the administration of diphosphonate com- 
pounds to prevent bioprosthetic heart valve 
calcification [ 71. Furthermore, controlled drug 
delivery matrices are in clinical use in a steroid- 
eluting cardiac pacing cat,heter (61, in which 
site-specific dexamethasone administration is 
utilized to prevent fibrous tissue buildup. These 
drug delivery systems were all fabricated from 
polymeric-based matrices, which are directly 
analogous to those used in the present arrhyth- 
mia studies. However, the matrices which were 
investigated in the present work differ from 
these other examples in their ability to deliver 
quickly a relatively large amount of their con- 
tained drug, thereby providing the opportunity 
for immediate conversion of a life-t,hreatening 
cardiac arrhythmia, ventricular t,achycardia, to 
a normal sinus rhythm. These functional dif- 
ferences are due to the unique fabrication and 
formulation conditions used which optimize 
matrix surface area exposure during the early 
phases of release. 
In conclusion, lidocaine-polyurethane con- 
trolled release matrices have been successfully 
formulated with a broad range of release rates, 
and have been shown t,o be efficacious via epi- 
cardial placement for the site-specific conver- 
sion of ouabain-induced ventricular tachycardia 
in dogs to normal sinus rhythm. 
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